Examining the Evolving 3L Treatment Landscape for mCRC

Author(s):

John Marshall, MD,Al B. Benson III, MD, FACP, FACCC, FASCO

Colorectal cancer specialists examine treatment sequencing strategies for third-line and subsequent therapy settings, while also evaluating regorafenib's efficacy and real-world outcomes.

EP: 1.Overview of Molecular Testing and Barriers in mCRC

EP: 2.Clinical Considerations for 2L Treatment Sequencing in mCRC

EP: 3.Novel Combination Regimens for 2L mCRC: Insights from ASCO 202

EP: 4.Exploring Toxicities for Second Line Treatments in mCRC

EP: 5.Existing Challenges for Patients Receiving 3L+ Therapies in mCRC

EP: 6.Factors Driving 3L Therapeutic Selection for mCRC

EP: 7.Exploring Data Outcomes From the SUNLIGHT Trial

EP: 8.Fruquintinib for mCRC: Data from the FRESCO & FRESCO-2 Studies

Now Viewing

EP: 9.Examining the Evolving 3L Treatment Landscape for mCRC

EP: 10.Additional Key Takeaways of ASCO 2024 Data in mCR

EP: 11.Future Outlooks in the Treatment of Metastatic Colorectal Cancer

Briefly Given the latest approvals, is there a continued role for regorafenib in mCRC and how do real-world outcomes support its use? (Yisilamu P, et al. ASCO 2024. Abstract e15562)
Dr Marshall to Panel:Let’s explore sequencing strategies for CRC in the 3L setting and beyond. Discuss how new data and other considerations impact treatment selection and sequencing.
1. Dr Marshall to Panel: How would you describe your current approach to treatment sequencing?
2. Dr Benson: How do you approach treating patients with fruquintinib from FRESCO and FRESCO-2 studies according to prior treatment sequence? (Bekaii-Saab T, et al. ASCO 2024. Abstract 3579.)
  1. Impact of prior bevacizumab
3. Dr Fakih:Please comment on recently presented data from the SUNLIGHT study and the implications on your treatment sequencing:
  1. Impact of prior fluoropyrimidine (Fakih, et al. ASCO GI 2024. Abstract 114)
  2. Impact of prior bevacizumab
4. Dr Cohen: Regorafenib and/or TAS-102 sequencing (Signorelli C, et al. ASCO 2024. Abstract e15553)